X4 Pharmaceuticals (XFOR) Net Income towards Common Stockholders (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Net Income towards Common Stockholders for 10 consecutive years, with -$16.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders rose 37.25% year-over-year to -$16.2 million; the trailing twelve-month figure through Jun 2026 stood at -$90.1 million (up 11.61% YoY), and the FY2025 full-year result was -$79.2 million, down 111.16% from the prior year.
• Net Income towards Common Stockholders climbed to -$16.2 million in Q2 2026 per XFOR's latest filing, from -$20.3 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $90.8 million in Q2 2024 and bottomed at -$55.7 million in Q2 2023.
• Historically, Net Income towards Common Stockholders has averaged -$19.5 million across 5 years, with a median of -$24.0 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Net Income towards Common Stockholders jumped 263.03% in 2024, then slumped 7438.41% in 2026.
• Over 5 years, Net Income towards Common Stockholders stood at -$29.1 million in 2022, then jumped by 34.27% to -$19.1 million in 2023, then sank by 108.2% to -$39.8 million in 2024, then soared by 39.95% to -$23.9 million in 2025, then surged by 32.44% to -$16.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$16.2 million, -$20.3 million, and -$23.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.